Сравнение
Melanotan II vs. Bremelanotide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
121062-08-6
189691-06-3
Молекулярная масса
1024.18 g/mol
1025.18 g/mol
Период полувыведения
1 h
2.7 h
Последовательность
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHМеханизм действия
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Доказательная база
Наивысшая доказательность
Исследование на людях
РКИ на людях
Исследования
9
5
из них на людях
5
5
Зафиксированные эффекты
4
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
6
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Melanotan II and Bremelanotide?
- Melanotan II is classified as "Исследования (прочее)", while Bremelanotide is classified as "Исследования (прочее)". Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Melanotan II or Bremelanotide?
- The highest available evidence level is "Исследование на людях" for Melanotan II and "РКИ на людях" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Melanotan II and Bremelanotide in Germany and the United States?
- Германия: Melanotan II — Не одобрено, Bremelanotide — Не одобрено. США: Melanotan II — Не одобрено, Bremelanotide — Рецептурный. These are factual summaries with source and review date on the individual pages.